Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ArcticZymes Technologies ASA ( (DE:B4V) ) has shared an update.
ArcticZymes Technologies ASA has entered into an exclusive distribution agreement with Brenntag Specialties Pharma for its SAN-HQ and M-SAN enzyme products across Europe. This collaboration is part of ArcticZymes’ new channel strategy, enhancing the accessibility of its innovative salt-active nucleases used in bioprocessing applications such as gene therapy and vaccine manufacturing. The partnership aims to expand ArcticZymes’ presence in Europe and support the growing therapeutic bioprocessing market by providing high-quality enzyme solutions.
More about ArcticZymes Technologies ASA
ArcticZymes Technologies ASA, based in Tromsø, Norway, is a publicly listed company specializing in the development and manufacturing of novel and high-quality enzymes for molecular research, diagnostics, and biomanufacturing. With over 30 years of expertise, the company focuses on salt-active nucleases and other specialty enzymes inspired by the Arctic environment, ensuring robust performance under demanding conditions. ArcticZymes is ISO 13485 certified and adheres to ICH GMP standards.
Average Trading Volume: 46,632
Current Market Cap: NOK1.53B
For an in-depth examination of B4V stock, go to TipRanks’ Overview page.